• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

KETAMINE Drug Record

  • Summary
  • Interactions
  • Claims
  • KETAMINE chembl:CHEMBL742 Approved

    Alternate Names:

    KETAMINE
    KETALAR
    NSC-70151

    Drug Info:

    Drug Class anesthetics
    Year of Approval 1970
    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications analgesic
    (2 More Sources)

    Publications:

    Rook Y et al., 2010, Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents., J Med Chem
    Smothers et al., 2007, Pharmacological characterization of glycine-activated currents in HEK 293 cells expressing N-methyl-D-aspartate NR1 and NR3 subunits., J. Pharmacol. Exp. Ther.
    Radovanović et al., [Ketamine: the past 30 years and its future]., Med. Pregl.
    Sinner et al., 2008, Ketamine., Handb Exp Pharmacol
    Harrison et al., 1985, Quantitative studies on some antagonists of N-methyl D-aspartate in slices of rat cerebral cortex., Br. J. Pharmacol.
    Li Y et al., 2015, CYP2B6*6 allele and age substantially reduce steady-state ketamine clearance in chronic pain patients: impact on adverse effects., Br J Clin Pharmacol
    Lang T et al., 2001, Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver., Pharmacogenetics
    Zanger UM et al., 2007, Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance., Pharmacogenomics
  • KETAMINE   GRIN3A

    Interaction Score: 3.09

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name amitriptyline + ketamine,Epicept NP-1
    Novel drug target Established target
    Trial Name nasal ketamine,Ereska

    PMIDs:
    17502428 14740534 18175098 2858237


    Sources:
    TdgClinicalTrial TEND

  • KETAMINE   CYP2B6

    Interaction Score: 1.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25702819 11470993 17638512


    Sources:
    PharmGKB

  • KETAMINE   GRIN2A

    Interaction Score: 1.03

    Interaction Types & Directionality:
    blocker (inhibitory)

    Interaction Info:

    PMIDs:
    20361801


    Sources:
    DTC

  • KETAMINE   GRIN1

    Interaction Score: 0.75

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20361801


    Sources:
    DTC

  • TdgClinicalTrial: KETAMINE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications analgesic
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • TEND: KETAMINE

    • Version: 01-August-2011

    Alternate Names:

    Drug Info:
    Year of Approval 1970
    Drug Class anesthetics

    Publications:

  • DTC: KETAMINE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL742 ChEMBL Drug ID

    Drug Info:

    Publications:
    Rook Y et al., 2010, Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents., J Med Chem

  • PharmGKB: ketamine

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Li Y et al., 2015, CYP2B6*6 allele and age substantially reduce steady-state ketamine clearance in chronic pain patients: impact on adverse effects., Br J Clin Pharmacol
    Zanger UM et al., 2007, Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance., Pharmacogenomics
    Lang T et al., 2001, Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver., Pharmacogenetics

  • TTD: Ketamine

    • Version: 2020.06.01

    Alternate Names:
    D0UM7O TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL742

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21